Author: admin

Bubble Vibez Expands Fleet to Spread Even More Bubble and Foam Party Joy

“Glow, foam, and fearless fun all in one jump!”
More trucks, more foam, more fun all across DFW!

Dallas-Fort Worth, TX – Jun 16, 2025 – Bubble Vibez, the DFW metroplex’s go-to source for unforgettable bubble parties, foam parties, and glow foam parties, is thrilled to announce the expansion of its bubble truck fleet! With the addition of a new vehicle, Bubble Vibez is now more equipped than ever to bring joy, laughter, and soapy fun to even more neighborhoods, schools, and special events throughout the region.

Known for delivering vibrant, interactive mobile experiences, Bubble Vibez specializes in turning everyday spaces into high-energy celebrations. Whether it’s a birthday bash, school field day, church event, community festival, or just a spontaneous burst of joy in your community, driveway, Bubble Vibez now has even greater availability and flexibility thanks to its growing fleet of its bubble trucks.

“Our mission is simple — spread love and fun with every bubble and every blast of foam,” said Danielle Faith, the Bubble Vibez Digital marketing team lead. “With our additonal vehicle now ready to roll, we can increase the fun and reach even more families, schools, and partygoers across the DFW area.”

BubbleVibez.com proudly offers:

  • Bubble Party Packages – Perfect for younger children and sensory-friendly fun.

  • Foam Party Experiences – High-energy, music-filled parties that transform outdoor spaces into a sea of bubbles and excitement.

  • Glow Foam Party Options – A nighttime hit featuring UV foam, glow sticks, and unforgettable vibes.

  • Custom Events – Tailored experiences for school carnivals, corporate events, or any gathering that needs a touch of bubbly magic.

With service extending across the entire Dallas-Fort Worth (DFW) metroplex, the Bubble Vibez crew is dedicated to delivering safe, energetic, and absolutely unforgettable events. The new bubble truck ensures faster booking options, quicker response times, and more flexibility for weekend and weekday events.

Families and event planners can now book with confidence knowing that Bubble Vibez is growing to meet the ever-increasing demand for bubble-powered fun.

Book your next party now at www.bubblevibez.com and let us bring the joy to you — anywhere in the DFW metroplex!

Media Contact
Company Name: Bubble Vibez
Contact Person: Tj Jawhari
Email: Send Email
Phone: (469) 200 – 6299
Address:2423 E Interstate 30
City: Rockwall
State: Texas
Country: United States
Website: bubblevibez.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bubble Vibez Expands Fleet to Spread Even More Bubble and Foam Party Joy

GRASSify Artificial Grass London Redefines Outdoor Living with Premium Synthetic Turf Solutions

GRASSify Artificial Grass London Redefines Outdoor Living with Premium Synthetic Turf Solutions

London, United Kingdom – June 16, 2025 – In a time where outdoor aesthetics, sustainability, and convenience intersect more than ever, GRASSify Artificial Grass London has emerged as a leader in providing cutting-edge, low-maintenance artificial grass solutions for residential, commercial, and public spaces. Strategically based at the Garden Centre, Unit 4 Old Kingston Rd, London KT4 7QH, GRASSify is proud to serve customers across Greater London and beyond with expertly installed, realistic synthetic grass designed to enhance the beauty and usability of any outdoor area.

Backed by years of experience and a commitment to quality, GRASSify delivers premium artificial lawns that look and feel like the real thing—without the hassle of watering, mowing, or seasonal deterioration. Whether you’re a homeowner seeking a pristine lawn, a business looking to upgrade your premises, or a school wanting a safe, clean play area, GRASSify offers the ideal solution.

A New Standard for Low-Maintenance Green Spaces

GRASSify is revolutionizing how Londoners approach landscaping by eliminating common challenges associated with natural grass. Mud, brown patches, bald spots, and hours spent on upkeep are now things of the past. With GRASSify’s innovative synthetic turf systems, clients enjoy a consistently lush and vibrant lawn all year long.

“Our mission is to simplify outdoor living while maintaining high standards of quality, beauty, and safety,” said a GRASSify spokesperson. “We offer products that are not only visually stunning but also durable, pet-friendly, and child-safe. We believe in transforming outdoor spaces into functional, enjoyable environments that require little to no maintenance.”

Designed with modern lifestyles in mind, GRASSify’s artificial grass products are ideal for urban gardens, family backyards, roof terraces, balconies, playgrounds, commercial spaces, and more.

Premium Products Backed by Innovation

At the heart of GRASSify’s offering is a curated collection of artificial grass products made using high-quality, UV-stabilised materials. These turfs are designed to withstand heavy foot traffic, varying weather conditions, and long-term exposure to sunlight—making them suitable for the UK’s ever-changing climate.

Each product features a soft, natural feel with variations in colour and blade texture to ensure a lifelike appearance. In addition to aesthetics, GRASSify’s grass products are manufactured to meet high safety standards:

  • Child- and pet-safe, with non-toxic materials

  • Drainage-efficient, preventing puddles and waterlogging

  • UV-resistant, to avoid fading over time

  • Hypoallergenic, ideal for sensitive individuals

  • Mud-free and mess-free, in any season

Whether the application is decorative or practical, GRASSify’s team ensures that each client receives the most appropriate solution based on their goals and budget.

Full-Service Installation by Trusted Professionals

GRASSify goes beyond simply supplying artificial grass—the company provides a comprehensive installation service, managing the entire process from start to finish. The experienced GRASSify team begins with an on-site consultation to assess the space, discuss requirements, and recommend the most suitable product options.

Services include:

  • Ground preparation and leveling

  • Professional fitting and cutting

  • Jointing and secure edge detailing

  • Waste removal and site cleanup

  • Aftercare guidance for long-term performance

Every project is executed with precision and care, ensuring a seamless and long-lasting result. Clients praise GRASSify for its clear communication, punctual service, and clean installation practices that minimize disruption.

A Trusted Partner for Residential and Commercial Projects

GRASSify has successfully completed projects for a wide variety of clients, from homeowners to property developers, schools, nurseries, and hospitality venues. With a service area that includes Central London, Greater London, Surrey, Kent, Essex, and surrounding counties, the company has built a reputation for reliability, quality, and customer satisfaction.

Some of GRASSify’s most common applications include:

  • Family gardens and front lawns

  • Apartment terraces and balconies

  • Pet zones and dog runs

  • School play areas and nurseries

  • Commercial courtyards and office entrances

  • Event installations and temporary landscaping

The team’s versatility and attention to detail have earned GRASSify consistent five-star reviews and ongoing referrals.

Supporting a Greener Future with Artificial Grass

In addition to offering convenience and aesthetic benefits, artificial grass is increasingly being embraced as a sustainable landscaping solution. GRASSify’s products significantly reduce water consumption, eliminate the need for harmful pesticides and fertilizers, and remove the carbon emissions associated with petrol-powered mowers and trimmers.

“Choosing artificial grass isn’t just a lifestyle choice—it’s also an environmentally conscious one,” the spokesperson added. “By installing our products, clients are making a responsible decision that contributes to reduced resource use and a lower ecological footprint.”

GRASSify continues to educate clients on the sustainability advantages of synthetic turf, while exploring new innovations and technologies to further enhance its product line and reduce environmental impact.

Media Contact
Company Name: GRASSify
Email: Send Email
Address:Garden Centre, Unit 4 Old Kingston Rd
City: London, KT4 7QH
Country: United Kingdom
Website: https://grassify.co.uk

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: GRASSify Artificial Grass London Redefines Outdoor Living with Premium Synthetic Turf Solutions

GRASSify Artificial Grass London Brings Premium, Sustainable Landscaping to Homes and Businesses Across the Capital

London, United Kingdom – June 16, 2025 – As more people seek sustainable, low-maintenance ways to enhance their outdoor spaces, GRASSify Artificial Grass London is leading the way with cutting-edge artificial grass solutions that blend beauty, performance, and environmental responsibility. Based at the Garden Centre, Unit 4 Old Kingston Rd, London KT4 7QH, GRASSify is helping homeowners, schools, businesses, and property developers across London and beyond to achieve evergreen landscapes—without the mud, mess, or maintenance.

From small city gardens to large commercial properties, GRASSify has built a reputation for delivering ultra-realistic synthetic grass that transforms outdoor spaces into functional, long-lasting areas for play, relaxation, or visual appeal. With a growing portfolio of successful projects and glowing customer testimonials, GRASSify is quickly becoming one of the most trusted names in artificial landscaping across the United Kingdom.

Changing the Way London Lives Outdoors

In today’s fast-paced world, time-consuming lawn maintenance is increasingly becoming a burden for many property owners. GRASSify offers a smarter solution: professionally installed artificial grass that looks just like natural turf—only better. With no mowing, watering, fertilising, or weeding required, customers can enjoy a perfectly green, clean, and tidy space year-round.

“At GRASSify, we believe everyone deserves a beautiful, hassle-free garden or outdoor area,” said a company spokesperson. “We provide not just premium artificial grass, but a full-service solution that enhances the lifestyle and property value of our customers.”

Whether it’s a compact urban balcony, a family garden, a school playground, or a commercial courtyard, GRASSify has a tailor-made solution that suits the needs of any environment.

The GRASSify Difference: Quality, Safety, and Innovation

What sets GRASSify apart is its commitment to quality and innovation. The company offers a wide selection of premium-grade artificial grass, crafted using advanced fibre technology and UV-resistant materials. These turfs are designed to mimic the look, colour variation, and soft texture of real grass—without any of its downsides.

Key product features include:

  • Pet- and child-friendly:

Made from non-toxic, hypoallergenic materials

  • UV-stabilised:

Maintains colour and integrity in direct sunlight

  • Quick drainage:

Prevents puddles and water build-up

  • Durability:

Withstands foot traffic, weather changes, and outdoor activities

  • Low maintenance:

No need for watering, mowing, or harmful chemicals

Available in a variety of pile heights, colours, and densities, GRASSify’s turf selection ensures that each installation complements the customer’s vision, lifestyle, and budget.

From Consultation to Completion: A Seamless Experience

GRASSify’s expert team takes pride in delivering a full-service experience. From the initial consultation and free quote to precision installation and aftercare guidance, customers are supported every step of the way.

The GRASSify process includes:

  • Site evaluation and design consultation

  • Groundwork and surface preparation

  • Turf cutting and expert installation

  • Jointing, edging, and clean-up

  • Long-term care advice and customer support

“Each project we take on is unique,” the spokesperson added. “We listen to our customers’ needs and tailor our services to ensure an outstanding, long-lasting result. Our goal is always customer satisfaction, and we’re proud of the trust we’ve built with hundreds of happy clients.”

Versatile Applications Across Sectors

GRASSify serves a wide range of clients, offering custom solutions for both residential and commercial landscapes. The company’s artificial grass has been installed in:

  • Private gardens – for a clean, low-maintenance outdoor space

  • Roof terraces and balconies – turning concrete into cosy green retreats

  • Schools and nurseries – for safe, all-weather play surfaces

  • Pet areas and kennels – providing hygienic and easy-to-clean zones

  • Office courtyards and retail spaces – enhancing curb appeal and usability

  • Events and exhibitions – for attractive, temporary green flooring

GRASSify’s flexibility and dedication make it the ideal partner for landscape designers, property developers, event planners, and local councils alike.

Supporting Eco-Friendly Urban Living

GRASSify isn’t just about aesthetics and convenience—it’s also about sustainability. Artificial grass eliminates the need for excessive water usage, harmful lawn chemicals, and petrol-fueled garden tools. As water conservation and eco-awareness become more critical in urban planning, GRASSify offers a landscaping solution that aligns with modern environmental values.

“Our clients care about their environmental impact, and so do we,” said the spokesperson. “By choosing artificial grass, they’re helping to save water, reduce emissions, and promote healthier outdoor environments.”

The company also continuously reviews its supply chain and product sourcing to ensure ethical, sustainable practices.

Media Contact
Company Name: GRASSify
Email: Send Email
Address:Garden Centre, Unit 4 Old Kingston Rd
City: London, KT4 7QH
Country: United Kingdom
Website: https://grassify.co.uk

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: GRASSify Artificial Grass London Brings Premium, Sustainable Landscaping to Homes and Businesses Across the Capital

Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics

The Key Non-Muscle Invasive Bladder Cancer Companies in the market include – CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Binhui Biopharmaceutical, SURGE Therapeutics, Pfizer, AstraZeneca, ImmunityBio, Inc., Guarionex J. Decastro, Janssen Research & Development, Tollys, Aura Biosciences, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, BristolMyers Squibb, Asieris Pharmaceuticals, and others.

 

DelveInsight’s “Non-Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Non-Muscle Invasive Bladder Cancer, historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Non-Muscle Invasive Bladder Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Muscle Invasive Bladder Cancer Market Forecast

 

Some of the key facts of the Non-Muscle Invasive Bladder Cancer Market Report:

  • The Non-Muscle Invasive Bladder Cancer market size was valued ~USD 2,350 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In January 2025, Pfizer Inc. (NYSE: PFE) has reported positive topline results from its Phase 3 CREST trial, which evaluated sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with Bacillus Calmette-Guérin (BCG) for patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial achieved its primary endpoint of event-free survival (EFS), as determined by investigators, demonstrating a statistically significant and clinically meaningful improvement when sasanlimab was combined with BCG (both induction and maintenance) compared to BCG alone.

  • In January 2025, Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotech company focused on next-generation precision therapies targeting FGFR (Fibroblast Growth Factor Receptor) biology, announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for TYRA-300. This clearance enables the initiation of a Phase 2 clinical trial for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). The trial will be overseen by Dr. Erik Goluboff, recently appointed as SVP of Clinical Development, who brings over three decades of expertise in urologic oncology and drug development.

  • In October 2024, Aura Biosciences, Inc. (NASDAQ: AURA) shared promising early data from its ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle invasive bladder cancer (NMIBC). So far, 13 patients have been enrolled, with the study’s primary focus on evaluating the safety and feasibility of locally administered bel-sar—both as a monotherapy (n=5) and in combination with light activation (n=8). Secondary objectives involve assessing biological activity and immune-related changes in the tumor microenvironment. Of the patients enrolled, 10 had low-grade and 3 had high-grade disease, consistent with the typical distribution in NMIBC. In the light-activated bel-sar group, 4 out of 5 low-grade patients achieved a clinical complete response (no tumor cells detected on histopathology), while 2 out of 3 high-grade patients demonstrated visible tumor reduction on cystoscopy.

  • In October 2024, UroGen Pharma initiated dosing in its Phase III UTOPIA clinical trial, marking the administration of the first dose of its investigational therapy, UGN-103 (mitomycin). This intravesical solution is being developed to treat low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The study aims to enroll 87 patients and will assess both the efficacy and safety of UGN-103 as a potential treatment option for this form of bladder cancer.

  • Among all risk categories, high-risk NMIBC had the largest market size in the 7MM, reaching approximately USD 1,600 million in 2023.

  • In the seven major markets (7MM), the United States recorded the highest number of cases in 2023, totaling approximately 600,000 prevalent cases. It is anticipated that these cases will continue to rise throughout the forecast period.

  • As per the projections, in Japan, NMIBC was most commonly found in the age group of 70-89, constituting roughly 60% of the total cases observed in 2023.

  • According to DelveInsight’s projections, approximately 600,000 prevalent cases of NMIBC were reported in the US in 2023.

  • As indicated by the American Urological Association and European Association of Urology, Non-Muscle Invasive Bladder Cancer (NMIBC) constitutes around 75% of all bladder cancer cases.

  • As per Valenza et al. (2022), approximately 20–40% of patients experience disease recurrences or persistence after undergoing BCG treatment, leading to their classification as BCG unresponsive.

  • Key Non-Muscle Invasive Bladder Cancer Companies: CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Binhui Biopharmaceutical, SURGE Therapeutics, Pfizer, AstraZeneca, ImmunityBio, Inc., Guarionex J. Decastro, Janssen Research & Development, Tollys, Aura Biosciences, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, BristolMyers Squibb, Asieris Pharmaceuticals, and others

  • Key Non-Muscle Invasive Bladder Cancer Therapies: CG0070, Sasanlimab (PF-06801591), UGN-102 (mitomycin), TAR-200, TARA-002, OH2 injection, STM-416, Durvalumab, BCG+N-803, Cabazitaxel, Cetrelimab, TL-532, AU-011, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, Nivolumab, APL-1202, and others

  • The Non-Muscle Invasive Bladder Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Muscle Invasive Bladder Cancer pipeline products will significantly revolutionize the Non-Muscle Invasive Bladder Cancer market dynamics.

 

Non-Muscle Invasive Bladder Cancer Overview

Non-Muscle Invasive Bladder Cancer (NMIBC) refers to a type of bladder cancer where the tumor is confined to the inner lining of the bladder and has not spread to the muscle layer. It is the most common form of bladder cancer, often detected through blood in the urine or urinary symptoms. Treatment typically involves transurethral resection, followed by surveillance for recurrence.

 

Get a Free sample for the Non-Muscle Invasive Bladder Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market

 

Non-Muscle Invasive Bladder Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Non-Muscle Invasive Bladder Cancer Epidemiology Segmentation:

The Non-Muscle Invasive Bladder Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Non-Muscle Invasive Bladder Cancer

  • Prevalent Cases of Non-Muscle Invasive Bladder Cancer by severity

  • Gender-specific Prevalence of Non-Muscle Invasive Bladder Cancer

  • Diagnosed Cases of Episodic and Chronic Non-Muscle Invasive Bladder Cancer

 

Download the report to understand which factors are driving Non-Muscle Invasive Bladder Cancer epidemiology trends @ Non-Muscle Invasive Bladder Cancer Epidemiology Forecast

 

Non-Muscle Invasive Bladder Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Muscle Invasive Bladder Cancer market or expected to get launched during the study period. The analysis covers Non-Muscle Invasive Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Muscle Invasive Bladder Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Non-Muscle Invasive Bladder Cancer Therapies and Key Companies

  • CG0070: CG Oncology

  • Sasanlimab (PF-06801591): Pfizer

  • UGN-102 (mitomycin): UroGen Pharma

  • TAR-200: Janssen Research & Development, LLC

  • TARA-002: Protara Therapeutics

  • OH2 injection: Binhui Biopharmaceutical

  • STM-416: SURGE Therapeutics

  • Durvalumab: AstraZeneca

  • BCG+N-803: ImmunityBio, Inc.

  • Cabazitaxel: Guarionex J. Decastro

  • Cetrelimab: Janssen Research & Development

  • TL-532: Tollys

  • AU-011: Aura Biosciences

  • VAX 014: Vaxiion Therapeutics

  • Pemigatinib: Incyte Corporation

  • Erdafitinib: Janssen Pharmaceuticals

  • TLD 1433: Theralase Technologies

  • Nivolumab: BristolMyers Squibb

  • APL-1202: Asieris Pharmaceuticals

 

Discover more about therapies set to grab major Non-Muscle Invasive Bladder Cancer market share @ Non-Muscle Invasive Bladder Cancer Treatment Landscape

 

Non-Muscle Invasive Bladder Cancer Market Strengths

  • Potent ICI-based gene therapies can alter the disease trajectory, halting its advancement to advanced stages—an impactful stride in managing NMIBC. Their potential to fulfill approval criteria further underscores their pivotal role in advancing NMIBC treatment.

  • Sasanlimab’s ease of subcutaneous administration and compelling clinical effectiveness position it as a standout candidate in the evolving field of cancer immunotherapy.

 

Non-Muscle Invasive Bladder Cancer Market Opportunities

  • The growing focus on research and development to introduce biomarkers for improved diagnosis and the exploration of combination therapy with BCG presents a promising opportunity in the NMIBC market.

  • The emergence of innovative treatments like CG0070, N-803, non-viral plasmid based therapy, and others signifies a promising advancement in NMIBC treatment. These therapies offer targeted and innovative approaches to address cancer.

 

Scope of the Non-Muscle Invasive Bladder Cancer Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Non-Muscle Invasive Bladder Cancer Companies: CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Binhui Biopharmaceutical, SURGE Therapeutics, Pfizer, AstraZeneca, ImmunityBio, Inc., Guarionex J. Decastro, Janssen Research & Development, Tollys, Aura Biosciences, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, BristolMyers Squibb, Asieris Pharmaceuticals, and others

  • Key Non-Muscle Invasive Bladder Cancer Therapies: CG0070, Sasanlimab (PF-06801591), UGN-102 (mitomycin), TAR-200, TARA-002, OH2 injection, STM-416, Durvalumab, BCG+N-803, Cabazitaxel, Cetrelimab, TL-532, AU-011, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, Nivolumab, APL-1202, and others

  • Non-Muscle Invasive Bladder Cancer Therapeutic Assessment: Non-Muscle Invasive Bladder Cancer current marketed and Non-Muscle Invasive Bladder Cancer emerging therapies

  • Non-Muscle Invasive Bladder Cancer Market Dynamics: Non-Muscle Invasive Bladder Cancer market drivers and Non-Muscle Invasive Bladder Cancer market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Non-Muscle Invasive Bladder Cancer Unmet Needs, KOL’s views, Analyst’s views, Non-Muscle Invasive Bladder Cancer Market Access and Reimbursement

 

To know more about Non-Muscle Invasive Bladder Cancer companies working in the treatment market, visit @ Non-Muscle Invasive Bladder Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Non-Muscle Invasive Bladder Cancer Market Report Introduction

2. Executive Summary for Non-Muscle Invasive Bladder Cancer

3. SWOT analysis of Non-Muscle Invasive Bladder Cancer

4. Non-Muscle Invasive Bladder Cancer Patient Share (%) Overview at a Glance

5. Non-Muscle Invasive Bladder Cancer Market Overview at a Glance

6. Non-Muscle Invasive Bladder Cancer Disease Background and Overview

7. Non-Muscle Invasive Bladder Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Muscle Invasive Bladder Cancer

9. Non-Muscle Invasive Bladder Cancer Current Treatment and Medical Practices

10. Non-Muscle Invasive Bladder Cancer Unmet Needs

11. Non-Muscle Invasive Bladder Cancer Emerging Therapies

12. Non-Muscle Invasive Bladder Cancer Market Outlook

13. Country-Wise Non-Muscle Invasive Bladder Cancer Market Analysis (2020–2034)

14. Non-Muscle Invasive Bladder Cancer Market Access and Reimbursement of Therapies

15. Non-Muscle Invasive Bladder Cancer Market Drivers

16. Non-Muscle Invasive Bladder Cancer Market Barriers

17. Non-Muscle Invasive Bladder Cancer Appendix

18. Non-Muscle Invasive Bladder Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics

Legendary Coaches Reflect on Historic State Championship Run in Latest Podcast Episode

“2025 Missouri Class 4 Girls Basketball State Title”
In a new podcast episode titled “MSHSAA Class 4 Girls Basketball State Champs”, coaches Adam Epps and Jimmy Blackwell revisit their thrilling journey to the 2025 Missouri Class 4 Girls Basketball State Title. With humor and heart, they share game highlights, personal stories, and the teamwork behind their championship win. Perfect for players, fans, and dreamers, the episode offers an inspiring behind-the-scenes look at their unforgettable season.

Doniphan – Jun 16th, 2025 – In the latest episode of their popular podcast, legendary coaches Adam Epps and Jimmy Blackwell take a trip down memory lane, reflecting on their unforgettable journey to the 2025 Missouri Class 4 Girls Basketball State Title.

Titled “MSHSAA Class 4 Girls Basketball State Champs”, the episode delves into the high drama and excitement of the season. With their signature comedic flair, the coaches share the highlights, challenges, and personal stories that defined their state championship victory. From game-winning strategies to off-the-court camaraderie, the episode offers a behind-the-scenes look at the hard work and determination that led to their historic run.

Listeners are treated to vivid retellings of pivotal moments — buzzer-beaters, halftime speeches, and many other intense moments that forged an unbreakable bond between players and coaches. The duo also gives shoutouts to the unsung heroes of the season: assistant coaches, supportive families, and the hometown fans who packed the stands week after week. Epps and Blackwell recount how the entire Doniphan community rallied behind the team, turning each game into a celebration of spirit and resilience.

“Basketball is more than just a game; it’s about community, teamwork, and the relentless pursuit of a dream,” says Adam Epps. Jimmy Blackwell adds, “We’re not just telling our story – we’re sharing the passion that every player, coach, and fan can relate to.”

Beyond game stats and final scores, the episode explores the personal growth and life lessons the athletes experienced throughout the season — grit, leadership, accountability, and joy in the journey. The coaches even revisit some of their favorite locker room jokes and motivational moments that kept the team grounded through the entire pressure-packed playoff run.

This episode is a must-watch for high school basketball players, fans, and anyone who has ever dreamed of seeing their team take home a state title. Whether you’re gearing up for your own basketball championship run or simply want to relive the magic of the Class 4 Missouri Basketball scene, this episode is packed with inspiration and insight.

Tune in to the episode here: Watch the episode

About the Podcast

Coaches Adam Epps and Jimmy Blackwell have been sharing their basketball wisdom, insights, and humor for years, offering an unparalleled look at the world of high school basketball. Their podcast offers a mix of motivation, strategy, and good-natured storytelling that fans and players alike have come to love.

Media Contact
Company Name: Ball, Bucks & Beards
Contact Person: Michael McAfee
Email: Send Email
Phone: 573-840-0510
City: Doniphan
State: Missouri
Country: United States
Website: https://www.youtube.com/@ballbucksbeards

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Legendary Coaches Reflect on Historic State Championship Run in Latest Podcast Episode

Alopecia Areata Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare

The Key Alopecia Areata Companies in the market include – Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others.

 

The Alopecia Areata market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alopecia Areata pipeline products will significantly revolutionize the Alopecia Areata market dynamics.

 

DelveInsight’s “Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Alopecia Areata market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Alopecia Areata market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alopecia Areata Market Forecast

 

Some of the key facts of the Alopecia Areata Market Report:

  • The Alopecia Areata market size was valued ~USD 379 million in 2023 and is anticipated to grow with a significant CAGR of 21% during the study period (2020-2034)

  • In March 2025, Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) have shared late-breaking findings from the Phase 3 BRAVE-AA-PEDS study, revealing that adolescents aged 12 to under 18 with severe alopecia areata (AA) achieved substantial hair regrowth on the scalp, eyebrows, and eyelashes after 36 weeks of once-daily oral baricitinib at 4 mg and 2 mg doses. The results were presented during a late-breaker session at the American Academy of Dermatology (AAD) Annual Meeting.

  • In February 2025, Q32 Bio has discontinued its Phase II trial of ADX-097, previously its lead candidate for renal disease, as part of a strategic shift toward advancing bempikibart for alopecia areata. Amid company restructuring and staff reductions, the U.S.-based firm confirmed the termination of its Phase II renal basket trial (NCT06419205) and announced plans to initiate an open-label extension of its ongoing Phase II SIGNAL-AA trial (NCT06018428).

  • In January 2025, Eirion Therapeutics Inc., a biopharmaceutical company focused on developing cutting-edge prescription products in aesthetics, reported encouraging results from its first-in-human clinical trial of ET-02, a topical medication designed to treat androgenic alopecia (age-related hair loss).

  • In July 2024, Sun Pharmaceutical Industries obtained approval from the US Food and Drug Administration (FDA) for LEQSELVI (deuruxolitinib), a treatment designed for managing an autoimmune disorder in adults.

  • In 2023, the alopecia areata market in the United States was valued at approximately USD 202 million, representing 53% of the global market share. This value is projected to rise notably with the launch of new and emerging therapies.

  • In 2023, the combined Alopecia Areata market size in the EU4 countries and the UK was estimated at around USD 146 million, accounting for nearly 39% of the total market revenue across the 7MM.

  • Within the EU4 and the UK, the United Kingdom held the largest share of the Alopecia Areata market in 2023, generating around USD 51 million. Spain followed with approximately USD 28 million, while France recorded the smallest market share at nearly USD 20 million that year.

  • In 2023, Japan’s Alopecia Areata market was valued at around USD 31 million, with projections indicating growth throughout the forecast period from 2024 to 2034.

  • According to estimates, OLUMIANT was the leading marketed drug for Alopecia Areata in 2023, generating around USD 180 million in revenue across the 7MM regions.

  • In 2023, the United States recorded the highest number of alopecia areata cases, with around 764,000 affected individuals. This figure is projected to rise by 2034, growing at a CAGR of 1.4%.

  • In 2023, the UK had the highest number of diagnosed prevalent cases of alopecia areata among the EU4 and the UK, with about 323,000 cases. Spain ranked next with roughly 170,000 cases, whereas Italy reported the lowest, at approximately 100,000 cases.

  • In 2023, Japan recorded an estimated 167,000 diagnosed prevalent cases of alopecia areata in females and 107,000 in males, with these figures expected to increase by 2034.

  • In 2023, women made up 63% of alopecia areata cases across the EU4 and the UK, while men accounted for 37%. These gender trends are anticipated to persist as overall prevalence rises by 2034.

  • In 2023, approximately 14% of alopecia areata cases in the EU4 and the UK were classified as mild, 45% as moderate, and 41% as severe. These severity trends are projected to persist, with the total prevalence expected to rise by 2034.

  • Key Alopecia Areata Companies: Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others

  • Key Alopecia Areata Therapies: OLUMIANT (baricitinib), LITFULO (ritlecitinib), Etrasimod, Coacillium (LH-8), PF-06651600, ADX-914, Upadacitinib, Daxdilimab, CTP-543, Deucravacitinib, SHR0302, IMG-007, Jaktinib, Rezpegaldesleukin, Rosnilimab, LEO 124249, Baricitinib, and others

  • The Alopecia Areata epidemiology based on gender analyzed that females and males are equally affected by Alopecia Areata

  • The Alopecia Areata epidemiology based on gender analyzed that Alopecia Areata affects both males and females equally

 

Alopecia Areata Overview

Alopecia Areata is an autoimmune disorder that causes sudden hair loss, typically in small, round patches on the scalp or other areas of the body. The condition occurs when the immune system mistakenly attacks hair follicles, disrupting hair growth. The exact cause is unknown, but genetics and environmental factors may play a role. While the condition can be unpredictable, hair often regrows over time, although in some cases, it can lead to permanent hair loss. Treatments focus on managing symptoms and stimulating hair regrowth, but there is no cure.

 

Get a Free sample for the Alopecia Areata Market Report:

https://www.delveinsight.com/report-store/alopecia-areata-market

 

Alopecia Areata Market

The dynamics of the Alopecia Areata market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

 

Alopecia Areata Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Alopecia Areata Epidemiology Segmentation:

The Alopecia Areata market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Alopecia Areata

  • Prevalent Cases of Alopecia Areata by severity

  • Gender-specific Prevalence of Alopecia Areata

  • Diagnosed Cases of Episodic and Chronic Alopecia Areata

 

Download the report to understand which factors are driving Alopecia Areata epidemiology trends @ Alopecia Areata Epidemiological Insights

 

Alopecia Areata Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched during the study period. The analysis covers Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alopecia Areata Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Alopecia Areata Therapies and Key Companies

  • RINVOQ (Upadacitinib): AbbVie

  • Bempikibart (ADX-914): Q32 Bio

  • Amlitelimab (SAR-445229): Sanofi

  • OLUMIANT (Baricitinib): Eli Lilly and Company/Incyte Corporation

  • LITFULO (Ritlecitinib): Pfizer

  • LEQSELVI (Deuruxolitinib, CTP 543): Sun Pharmaceuticals

  • ADX-914: Q32 Bio Inc.

  • Upadacitinib: AbbVie

  • Daxdilimab: Amgen

  • CTP-543: Concert Pharmaceuticals

  • Deucravacitinib: Bristol-Myers Squibb

  • SHR0302: Reistone Biopharma

  • IMG-007: Inmagene LLC

  • Jaktinib: Suzhou Zelgen Biopharma

  • Rezpegaldesleukin: Nektar Therapeutics

  • Rosnilimab: AnaptysBio, Inc.

  • LEO 124249: LEO Pharma

  • Baricitinib: Eli Lilly and Company

 

To know more about Alopecia Areata treatment, visit @ Alopecia Areata Medications

 

Alopecia Areata Market Strengths

  • The major strength of the Alopecia areata market is its robust pipeline with the emergence of several therapies

  • Increasing awareness and development to understand the diversity of the disease might improve the diagnosis of Alopecia areata, thereby resulting in a lucrative market opportunity

 

Alopecia Areata Market Opportunities

  • Several organizations are actively working to provide information and awareness of such rare and devastating disorder

  • The current treatment options only focus on palliative treatment rather than cure, which opens a platform of new therapies to boost the market of Alopecia areata

 

Scope of the Alopecia Areata Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Alopecia Areata Companies: Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others

  • Key Alopecia Areata Therapies: OLUMIANT (baricitinib), LITFULO (ritlecitinib), Etrasimod, Coacillium (LH-8), PF-06651600, ADX-914, Upadacitinib, Daxdilimab, CTP-543, Deucravacitinib, SHR0302, IMG-007, Jaktinib, Rezpegaldesleukin, Rosnilimab, LEO 124249, Baricitinib, and others

  • Alopecia Areata Therapeutic Assessment: Alopecia Areata current marketed and Alopecia Areata emerging therapies

  • Alopecia Areata Market Dynamics: Alopecia Areata market drivers and Alopecia Areata market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Alopecia Areata Unmet Needs, KOL’s views, Analyst’s views, Alopecia Areata Market Access and Reimbursement

 

Discover more about therapies set to grab major Alopecia Areata market share @ Alopecia Areata Treatment Landscape

 

Table of Contents

1. Alopecia Areata Market Report Introduction

2. Executive Summary for Alopecia Areata

3. SWOT analysis of Alopecia Areata

4. Alopecia Areata Patient Share (%) Overview at a Glance

5. Alopecia Areata Market Overview at a Glance

6. Alopecia Areata Disease Background and Overview

7. Alopecia Areata Epidemiology and Patient Population

8. Country-Specific Patient Population of Alopecia Areata

9. Alopecia Areata Current Treatment and Medical Practices

10. Alopecia Areata Unmet Needs

11. Alopecia Areata Emerging Therapies

12. Alopecia Areata Market Outlook

13. Country-Wise Alopecia Areata Market Analysis (2020–2034)

14. Alopecia Areata Market Access and Reimbursement of Therapies

15. Alopecia Areata Market Drivers

16. Alopecia Areata Market Barriers

17. Alopecia Areata Appendix

18. Alopecia Areata Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alopecia Areata Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare

“I Am Crazy… And You Are, too!” – A Raw, No-Nonsense Book Serves as a Wake-Up Call for a World That’s Lost Its Mind

Author David Schecter Challenges Readers to Stop Faking It and Start Thinking

Let’s get something out of the way: if you’re looking for a warm, fuzzy self-help book that tells you to take deep breaths and repeat mantras in the mirror — this isn’t it.

I Am Crazy… And You Are, too! is a brutally honest, laugh-out-loud, jaw-droppingly real punch to the mental gut. Author David Schecter doesn’t just nudge you toward self-reflection — he kicks the door down, throws your comfort zone out the window, and asks one thing:

Are you done pretending yet?

This book isn’t about being polite. It’s about being real. It’s for people who are sick of nonsense — the kind that shows up in fake friendships, people-pleasing behavior, social media masks, toxic relationships, and watered-down truths. David doesn’t just dissect what’s wrong — he shows you how to live better: with clarity, purpose, and unapologetic self-respect.

And no, it’s not religious. It’s not political. It’s not New Age.

It’s just real.

Schecter writes like a man who’s been through the fire and came out with his eyebrows singed but his soul intact. The reflections in this book aren’t rehearsed, polished, or filtered. They’re carved out of pain, solitude, laughter, and an unshakable belief in personal truth.

What the Book Does (and Doesn’t Do)

You won’t find chapters here about “positive affirmations” or “vibration levels.” You will find:

The beauty of solitude — and why it beats chaos every time

How to spot (and drop) people who drain your energy

Why pain is the best teacher you never asked for

A takedown of groupthink, people-pleasing, and emotional manipulation

How to build your life back from rock bottom with nothing but logic, guts, and grit

Schecter’s writing hits hard because it’s not sugar-coated. Every page reads like a brutally honest letter from someone who finally decided to stop lying to themselves — and wants you to do the same.

About the Author: David Schecter

David Schecter has worn more hats than most people own socks. With a BSBA in Marketing and an MBA from the University of Denver, he built a successful corporate career with over five years of experience in market research, development, and forecasting across industries as diverse as mining, oil, lumber, shipping, and consumer goods.

But boardrooms were just one chapter. David’s life includes real estate development (residential and industrial), ownership of several small businesses — including a country bar and car washes — and creative projects like cookbooks and calendars. He’s served on nonprofit boards, worked on multi-million-dollar real estate projects, and actively participated in church councils.

He’s also a single father who spent years coaching his sons’ sports teams, prioritizing family over everything else. Oh, and did we mention he plays piano and sings in public?

But what truly sets David apart isn’t his résumé — it’s his mindset. He’s seen success. He’s faced failure. And both have shaped his deep skepticism of conformity and the systems that pressure people to act “normal.” In I Am Crazy… And You Are, too!, he invites readers to reject performative living and embrace the power of authenticity. No filters. No fake smiles. Just raw truth, lived out loud.

Why This Book Matters Now

We’re living in an age where attention is currency and validation is an addiction. Everyone’s trying to fit in — and in the process, we’re losing who we are.

David Schecter isn’t having it.

This book is a permission slip to stop pretending, cut the noise, and reclaim your voice. Whether you’re lost, burnt out, fed up, or just tired of editing yourself to make others comfortable — I Am Crazy… And You Are, too! might just be the most honest thing you’ll read this year.

No fluff. No gurus. Just one man telling the truth.

And maybe, just maybe, reminding you that you’re not the crazy one after all.

To learn more, visit:

https://www.youtube.com/@DavidB.Schecter

https://www.linkedin.com/company/david-b-schecter

https://www.facebook.com/davidbschecter

https://www.instagram.com/davidbschecteroffi/

https://x.com/davidbscheecter

Media Contact
Company Name: Visionary Book Writers
Contact Person: James Allen
Email: Send Email
City: St. Petersburg
State: FL
Country: United States
Website: www.instagram.com/davidbschecteroffi

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: “I Am Crazy… And You Are, too!” – A Raw, No-Nonsense Book Serves as a Wake-Up Call for a World That’s Lost Its Mind

David Schecter’s Book “I Am Crazy… And You Are, Too!” Cracks the Mask of “Normal” and Asks: What If We’re All Just a Little Off, and That’s Okay?

David Schecter doesn’t want to fix you. He wants you to look at yourself honestly, laugh at the chaos, and finally breathe. His debut book, I AM CRAZY …AND… YOU ARE TOO!, is an unfiltered, deeply personal, and often laugh-out-loud funny ride through the mental junk drawers we all try to keep shut.

This is not a book of polished answers…it’s a flashlight aimed into the attic of your mind.

With sharp insight and unapologetic candor, Schecter explores why we make the choices we do, why we repeat the same painful patterns, and how we might finally stop. From fear and ego to religion, government, addiction, and personal accountability—he holds nothing back, all while keeping a tone that’s conversational, never condescending. This is the guy who tells it to you straight because he actually gives a damn.

At the heart of it all? One question: What if the real reason life feels overwhelming is that we’re afraid to be real?

Not Advice. Not a Lecture. Just Truth…And a Bit of Madness

I AM CRAZY …AND… YOU ARE TOO! is split into two distinct parts: the first looks inward, urging readers to reflect on themselves—their rules, priorities, fears, and contradictions. The second zooms out, examining the systems we live in—education, crime, religion, society—and how easily they distract us from authenticity.

Through it all, Schecter reminds us that you don’t need a full personality overhaul. You just need to start being honest—with yourself first. Maybe you’re not as lost as you think. Maybe the world’s just loud and messy, and you’ve never had a safe space to ask the real questions.

Until now.

About the Author: David Schecter

David Schecter doesn’t write from a mountaintop—he writes from experience. With a BSBA in Marketing and an MBA from the University of Denver, David began his career in corporate America, working in market research, forecasting, and development across a wide range of industries, from mining and oil to consumer goods.

But his story doesn’t end with boardrooms and data. He’s also built homes, created cookbooks, opened businesses (including a country bar and multiple car washes), and served on nonprofit boards and church councils. His hands-on experience in both industry and community gives him a rare, grounded perspective on what matters—and what doesn’t.

A devoted single father, he spent years coaching his sons’ sports teams and keeping family at the center of his world. He’s also a pianist and singer, performing publicly and bringing a creative side to his structured world. His life, as he openly shares, has had both success and setbacks—and those ups and downs are exactly what make his voice relatable.

In I AM CRAZY …AND… YOU ARE TOO!, David channels that lifetime of doing, failing, building, and learning into one clear message: Think for yourself. Be yourself. Stop letting society do the steering. His writing is an invitation—not to rebel blindly, but to live truthfully, with self-awareness and compassion.

A Book for the Brave (and the Curious)

I AM CRAZY …AND… YOU ARE TOO! is for anyone who’s ever thought, “Something’s off, and maybe it’s not just me.” It’s for the overthinkers, the seekers, the quietly overwhelmed—and the ones who are finally ready to pull off the mask and see what’s underneath.

Now available on Amazon.Read it. Question it. Live with it.Just don’t expect to stay the same.

To learn more, visit:

https://www.youtube.com/@DavidB.Schecter

https://www.linkedin.com/company/david-b-schecter

https://www.facebook.com/davidbschecter

https://www.instagram.com/davidbschecteroffi/

https://x.com/davidbscheecter

Media Contact
Company Name: Visionary Book Writers
Contact Person: James Allen
Email: Send Email
City: St. Petersburg
State: FL
Country: United States
Website: www.instagram.com/davidbschecteroffi

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: David Schecter’s Book “I Am Crazy… And You Are, Too!” Cracks the Mask of “Normal” and Asks: What If We’re All Just a Little Off, and That’s Okay?

Why Being ‘Crazy’ Might Be the Sanest Choice – Inside David Schecter’s Eye-Opening Book

Discover the liberating truth about yourself and the world in this refreshingly candid new book

David Schecter’s I Am Crazy… And You Are, Too! shatters conventional thinking about happiness, self-awareness, and the chaos that governs modern life. With sharp wit and heartfelt honesty, Schecter invites readers to embrace their inner quirks and break free from the suffocating grip of societal rules. This is not your typical self-help book — it’s a compelling call to live authentically, question everything, and find freedom in imperfection.

The premise is simple yet profound: everyone is a little crazy, and accepting this fact can be the key to a happier, more meaningful life. Schecter challenges readers to rethink the rules that bind them — the endless “shoulds” imposed by society, family, and government — and replace them with one guiding principle: the Golden Rule. Through a blend of humor, sharp observation, and real-life stories, he explores how self-understanding, balance, courage, and forgiveness pave the road to personal freedom and genuine happiness.

This compelling, candid book will resonate with anyone who’s ever felt constrained by society’s expectations or lost in the noise of everyday life. Schecter’s invitation to embrace imperfection, challenge authority, and live by one simple but profound rule will inspire readers to rethink their own journeys and reclaim control over their happiness.

The book goes beyond the surface, digging deep into the messy parts of life that people often avoid. From the traps of fear and ego to the complexity of addiction and the overwhelming pressure of choices, Schecter offers no-nonsense insights to help readers take control of their own minds and lives. His message is clear: happiness isn’t about fitting in or pleasing others — it’s about thinking for yourself, accepting your flaws, and living by your own truth.

David’s writing is persuasive but never preachy, giving readers a sense of a wise friend nudging them toward self-discovery rather than a dictator laying down rules. His perspective is both down-to-earth and invigorating, reminding us that life’s challenges are universal and that we all have the power to transform our outlook — one honest thought at a time.

About the Author

David Schecter holds a BSBA in Marketing and an MBA from the University of Denver and brings over five years of corporate experience across industries including mining, oil, lumber, shipping, and consumer goods. Beyond the business world, David’s diverse life experiences range from developing cookbooks and calendars to owning a country bar and multiple car washes. He is deeply involved in real estate projects worth millions and has contributed time to nonprofit boards and church councils.

As a single father, David coached his sons’ sports teams, emphasizing the importance of family above all. He also performs piano and sings publicly, reflecting his passion for creativity and connection. David has encountered significant successes and setbacks throughout his life, shaping his unique perspective on conformity, government, and personal freedom.

In I Am Crazy… And You Are, Too!, David urges readers to reject the pressure of social approval and embrace their authentic selves. His approachable yet powerful voice encourages everyone to think independently, question inherited rules, and choose personal truth as the path to happiness. This book is a manifesto for those ready to live boldly and unapologetically.

I Am Crazy… And You Are, Too! is now available on Amazon and the official website.

To learn more, visit:

https://www.youtube.com/@DavidB.Schecter

https://www.linkedin.com/company/david-b-schecter

https://www.facebook.com/davidbschecter

https://www.instagram.com/davidbschecteroffi/

https://x.com/davidbscheecter

Media Contact
Company Name: Visionary Book Writers
Contact Person: James Allen
Email: Send Email
City: St. Petersburg
State: FL
Country: United States
Website: www.instagram.com/davidbschecteroffi

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Why Being ‘Crazy’ Might Be the Sanest Choice – Inside David Schecter’s Eye-Opening Book

David Schecter’s Latest Book, “I Am Crazy… And You Are, Too!” Is the Sanity Check Everyone Needs

Imagine a book that doesn’t try to fix you, flatter you, or fake its way into your heart. Now imagine it’s staring you down and saying, “You’re not crazy for thinking the world is nuts—because it is.” That’s the tone of David Schecter’s I Am Crazy… And You Are, Too!—a brutally clear-eyed, hilarious, and oddly comforting punch to the collective gut.

Forget the empty optimism. This isn’t a manifesto for positivity. It’s a candid, clever, sometimes rude but always honest reminder that we’ve all been sold a version of life that doesn’t quite add up—and David Schecter isn’t afraid to rip the cover off the whole operation.

This is not a book of “steps.” No secret formula. No glossy promises. What Schecter gives readers is something better: a flashlight and full permission to start poking around in the dark corners of their own thinking—and everyone else’s.

Why This Book Might Make You Squirm (And Why That’s a Good Thing)

Schecter splits his book into two equally fearless sections. First up? You. Yes, you. Not your social profile or polite public face. The real you. The one who panics at night, zones out at work, and plays mental ping-pong between “I’m doing great” and “What’s the point?”

He calls out the emotional shortcuts we take, the mental gymnastics we perform to stay comfortable, and the everyday compromises that slowly strangle authenticity. And he does it in a voice that feels less like a lecture and more like a friend shaking your shoulders saying, “Snap out of it!”

Then he zooms out. Cue the second half of the book, where he takes on society—our politics, our belief systems, our rules, and our quiet agreements to keep pretending that it’s all working. Spoiler: It’s not. And Schecter doesn’t just notice; he makes you notice, too.

But this isn’t a tantrum in book form. It’s full of humor, honesty, and hard-earned insight. You’ll laugh. You’ll probably wince. And you might even feel relieved that someone is finally saying the things we’re all thinking.

About David Schecter: A Man Who’s Actually Done the Stuff People Write About

David Schecter is not a theorist. He’s not a TED Talk in human form. He’s a guy who’s lived, built, lost, rebuilt, and kept showing up—just in a slightly weirder, more observant way than most.

He holds a BSBA in Marketing and an MBA from the University of Denver, but his education didn’t stop there. He dove headfirst into corporate life—working across mining, oil, lumber, shipping, consumer goods, and more—learning what made industries tick, and where the gears started grinding.

Not content with boardrooms alone, he launched real estate ventures worth millions, developed both residential and industrial properties, and started businesses that ranged from car washes to a country bar. He even got involved in publishing cookbooks and calendars.

Schecter is a single father who coached his sons’ sports teams while juggling business meetings and property deals. He’s served on nonprofit boards and church councils. And just to keep things weird in the best way—he sings and plays piano in public.

Through it all, one thing stayed consistent: his ability to call BS when he sees it. And he sees a lot. That’s what drives this book—not arrogance, but the hard-earned realization that too many people are following a script that doesn’t work for them.

This Isn’t a Book. It’s a Dare.

If you’re someone who’s ever felt exhausted by the act of pretending—pretending you’re fine, pretending the system makes sense, pretending you believe what you’re supposed to—this book might sting a little. But it also might wake you up.

Schecter isn’t here to comfort you. He’s here to hand you the keys to your own brain, and maybe blow open a few doors along the way.

He’s not asking you to believe him. He’s just asking you to believe yourself—for once.

“I Am Crazy… And You Are, Too!” is available now.

To learn more, visit:

https://www.youtube.com/@DavidB.Schecter

https://www.linkedin.com/company/david-b-schecter

https://www.facebook.com/davidbschecter

https://www.instagram.com/davidbschecteroffi/

https://x.com/davidbscheecter

Media Contact
Company Name: Visionary Book Writers
Contact Person: James Allen
Email: Send Email
City: St. Petersburg
State: FL
Country: United States
Website: www.instagram.com/davidbschecteroffi

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: David Schecter’s Latest Book, “I Am Crazy… And You Are, Too!” Is the Sanity Check Everyone Needs